Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
The brand will establish an integrated hearing care ecosystem at Neuberg Diagnostics centers across the length and breadth of the country
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
These accolades highlight our unwavering commitment to maintaining the highest safety standards
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
